Document is current
Any future updates will be listed below
-
Authors
Cagigas, Maria L.
Fiorito, Giovanni
Bertozzi, Beatrice
Masedunskas, Andrius
Cava, Edda
Spelta, Francesco
Veronese, Nicola
Tosti, Valeria
Rajakumar, Gayathiri
Pelaia, Tiana
Bullock, Arnold D.
Figenshau, Robert S.
Andriole, Gerald L.
Fontana, Luigi http://orcid.org/0000-0001-8500-5537
- License Information
-
More Information
Article History
Received: 20 May 2024
Accepted: 4 July 2024
First Online: 22 July 2024
Declarations
:
: This study focuses on the secondary outcome (IGF-1 axis) of the trial “Does Protein Restriction Inhibit Prostrate Cancer Growth” (registry: ; registration number:NCT01692587; registration date: 2012–09-07). This was a randomized controlled trial performed at Washington University in St. Louis in the United States, aimed to evaluate the effects of isocaloric PR in otherwise healthy men diagnosed with localized prostate cancer. The study adhered to the Declaration of Helsinki 1975 (1983), and the protocol was approved by the institutional review board of Washington University Medical School, St. Louis, MO, United States (IRB #201011804). Written informed consent was obtained from all study volunteers, and oversight was provided by a data and safety monitoring board.
: All data presented in this publication are de-identified and do not contain individual information.
: The authors report no conflicts of interest.
